Entries by CAPTIS

Pfizer to buy Array BioPharma for £9.06bn

Array BioPharma is involved in the discovery, development and commercialisation of targeted small molecule medicines for the treatment of cancer and other high-burden diseases. The company sells Braftovi The post Pfizer to buy Array BioPharma for £9.06bn appeared first on Pharmaceutical Business review.

Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria

Sustained efficacy of ULTOMIRIS was observed on the co-primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase (LDH) levels and the secondary endpoints of LDH level reduction The post Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria appeared first on Pharmaceutical Business review.

Corvidia Therapeutics initiates phase 2b dose-finding study for Ziltivekimab

Previously known as COR-001, ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). The post Corvidia Therapeutics initiates phase 2b dose-finding study for Ziltivekimab appeared first on Pharmaceutical Business review.

FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti

The FDA has approved Kanjinti for all approved indications of the reference product Herceptin to treat HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal The post FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti appeared first on Pharmaceutical Business review.

Pfizer announces results from XELJANZ XR ORAL Shift study

Patients who achieved low disease activity (LDA) with XELJANZ (tofacitinib) extended release (XR) 11 mg once daily (QD) plus methotrexate (MTX) after a 24-week open-label run-in period, were The post Pfizer announces results from XELJANZ XR ORAL Shift study appeared first on Pharmaceutical Business review.